Campath in Leukemia Yields to Lemtrada in Multiple Sclerosis
Sanofi SA is withdrawing the leukemia drug Campath (alemtuzumab), a major bone of contention during the fractious negotiations preceding its 2011 acquisition of Genzyme Corp., in favor of rebranding the CD52-targeting antibody as Lemtrada in the planned indication of multiple sclerosis (MS).
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter